New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSelank vs Cardiogen

Selank vs Cardiogen

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Selank
Anti-Aging & Longevity
Cardiogen
Summary
Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Half-Life
Minutes (but effects persist for hours)
Short (minutes); gene-regulatory effects persist longer
Admin Route
SubQ, Intranasal
SubQ, Oral
Research
Typical Dose
250–500 mcg
10 mg per day
Frequency
1–3 times daily
Daily for 10–30 days
Key Benefits
  • Reduces anxiety without sedation
  • Enhances memory and learning
  • Improves focus and concentration
  • Stabilizes mood
  • Reduces physiological stress response
  • May enhance motivation
  • No addiction potential or withdrawal
  • Fast-acting — effects within 20–30 minutes
  • Approved clinically in Russia for anxiety disorders
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
Side Effects
  • Mild sedation at higher doses (paradoxical)
  • Fatigue (rare)
  • Irritability during discontinuation (uncommon)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
Stacks With